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Abstract
Chronic obstructive pulmonary disease (COPD) represents a socio-economic burden and requires regular and
ongoing treatment. Inhalation therapy is recommended at all stages of the disease and allows the delivery of active
molecules directly to the target site of action, whilst minimising adverse side-effects. Inhalers therefore play a crucial
role in the effective management of patients with COPD and their choice is as important as that of the drug. The
three most important factors that influence inhaled drug deposition within the airways are the patient’s inhalation
flow, the aerosol velocity, and the inhaled drug particle size. These ultimately impact on the amount of drug
reaching the target site and therefore the functional and clinical responses of the patient. Furthermore, patients’
training and education in the use of inhalers have been shown to be directly related to the efficacy of the therapy.
However, in daily clinical practice, too little consideration is given to the features of the different inhalers and to
the ability of patients to properly handle the device, and precise recommendations are greatly needed to help
healthcare professionals to advise and prescribe the most ‘appropriate’ inhaled drug/device product. The present
review aims to provide the latest evidence on the importance of the inhaler device in the management of
patients with COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) repre-
sents a major global concern for national healthcare sys-
tems, being ranked as the fourth leading cause of death
in the world and significantly affecting the quality of life
of patients [1, 2]. COPD is characterised by persistent
airway inflammation and bronchial obstruction and re-
quires regular and ongoing treatment. Inhalation therapy
is the mainstay of treatment in patients with COPD,
where bronchodilators (beta-2 agonists, anti-muscarinic
agents) and anti-inflammatory drugs (corticosteroids)
are recommended by international strategy documents
at any stage of the disease [3]. In contrast, oral treat-
ments such as theophylline, phosphodiesterase-4 inhibi-
tors and corticosteroids are only occasionally used.
Indeed, inhaled treatment has several advantages over
oral therapy as inhalation allows the delivery of active
molecules directly to the target site of action, whilst
minimising adverse side-effects. Furthermore, a lower
drug dose is needed to achieve the therapeutic effect via
the inhaled route and the onset of action is more rapid,
in contrast with oral administration [4].
Inhalers, therefore, play a crucial role in the manage-
ment of patients with COPD and it is being recognised
that the choice of the inhalation device appears to be as
important as that of the drug molecule [5]. Indeed in
daily clinical practice, pulmonologists usually focus on
the pharmacological properties of the various respiratory
drugs in selecting the best possible therapeutic option,
but little consideration is given to the features of the dif-
ferent inhalers and to the ability of the patient to use the
device, which are topical issues [6]. In fact it is often un-
derappreciated that incorrect inhalation technique by
the patient is directly associated with increased health-
care resource utilisation [7–9].
Furthermore, with increasingly constrained societal
healthcare budgets and expiring patent protection for
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many branded medications, there is emphasis on the de-
velopment of generic inhaled drugs that are therapeutic-
ally equivalent to the original registered products, but
may differ in their formulation and the design of the in-
halation device. This growing scenario poses practical
clinical questions about the potential impact of switch-
ing from branded to generic inhaler products in man-
aging patients with COPD [10]. Indeed, the estimated 10
new drug product launches in COPD over the next
2 years [11, 12] will lead to even more confusion, and
apathy, in respiratory prescribing, as there are currently
more than 250 inhaler products in pharmaceutical for-
mularies [13] and direction is greatly needed to help
healthcare professionals advise and prescribe the ‘appro-
priate’ inhaled drug/device product for patients.
The present review article aims to provide the latest
evidence on the importance of the inhaler device in the
management and treatment of patients with COPD, and
specifically to collect data to support decisions on the
appropriate choice of device by healthcare professionals.
It also addresses and contrasts the advantages and limi-
tations of different available inhalation device options.
Review
Methodology
Papers were identified through a search strategy run in
the principal electronic database (Pubmed, ISI Web of
Knowledge, CENTRAL) from the date of inception up
to 10th March 2015. The following key-words were se-
lected: “chronic obstructive pulmonary disease”,
“COPD”, “device” and “inhaler”. No restriction was
placed on study design and language of publication.
Choosing an inhaler device
The goal of therapy in managing patients with COPD is
to obtain full control of their symptoms and prevent dis-
ease exacerbations, by delivering the optimal inhaled
drug dose to the target site of action in the lungs, with
minimal or no adverse side-effects [3]. Despite the clin-
ical importance of inhaled therapy in treating patients
with COPD, current literature seems to lack a unified
consensus on the standards for choosing and prescribing
inhalation devices, whereas in contrast healthcare pro-
fessionals are usually comfortable in treating patients
based on the pharmacological properties of the drug
molecule. In 2005, Dolovich and colleagues, on behalf of
the American College of Chest Physicians (ACCP) and
of the American College of Asthma, Allergy, and Im-
munology (ACAAI) published evidence-based guidelines
to provide recommendations on inhaler device selection
and assessed the outcomes of aerosol therapy [14]. Their
systematic review and meta-analysis of randomized con-
trolled trials (RCT’s) showed no significant difference
between devices for any efficacy outcome in any clinical
setting of patients investigated, while adverse side-effects
were minimal and were primarily related to a higher de-
livered drug dose. The authors suggested that when
selecting an aerosol delivery device, the choice should be
based on several parameters, such as drug availability
and administration time, patient age and ability to use
the device correctly, convenience in both outpatient and
inpatient settings, costs, as well as physician and patient
preference. More recently, a position paper produced by
a joint task force of the European Respiratory Society
(ERS) and the International Society for Aerosols in
Medicine (ISAM) provided indications for choosing the
best inhaler device based on the patients’ disease, level
of inspiratory flow, population, clinical setting and inhal-
ation technique [15]. However, less than 2 % of the Global
Initiative for Obstructive Lung Disease (GOLD) strategy
document for patients with COPD focusses on device-
related issues [16]. In contrast the new GINA strategy
document for asthma now places the assessment of the
patient’s inhalation technique and prescription of the ap-
propriate device as a key component in their treatment al-
gorithms [17].
The three most important factors that influence in-
haled drug deposition within the airways is the patient’s
inhalation flow, the aerosol velocity, and the inhaled
drug particle size; these factors ultimately impact on the
amount of drug reaching the airways and therefore, the
functional and clinical responses of the patient [18]. The
choice of an inhalation device in patients with COPD
should therefore be mainly driven by these parameters.
Inhalation flow and aerosol velocity
Achieving the correct inhalation flow from any inhal-
ation device is critical in order for the patient to achieve
therapeutic benefit from the inhaled drug. However,
many patients use inhalers incorrectly and their subopti-
mal use directly affects clinical efficacy. The key concern
in this scenario is that healthcare professionals often at-
tribute lack of clinical efficacy with the pharmacological
properties of the drug, rather than the inability of the
patient to use the inhalation device properly. Conse-
quently, doctors increase the drug dose delivered to the
patient, leading to the potential for greater toxicity and
adverse side-effects, which could have been avoided by
attending to the patient-device interaction. With pres-
surised metered dose inhalers (pMDIs), the failure to in-
hale slowly and deeply is often a greater problem that
poor coordination [19]; indeed, patients inhale too fast
from pMDIs potentially leading to greater impaction of
the aerosolised drug in the back of the throat and less
drug reaching the lungs [20]. In contrast, dry powder
inhalers (DPIs) require much higher inhalation flows
that pMDIs, and not using a forceful and deep inspir-
ation from DPIs is a critical problem [21]. Certainly
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most DPIs are highly dependent on the patient’s inhal-
ation flow (flow-dependency) and sometimes inhalation
flows ≥60 l/min are required to de-aggregate and dis-
perse the drug powder. Patients with COPD use sub-
optimal inhalation flows from DPIs as they may not
have the energy generated by their inspired breath to
achieve the effective inhalation flows that are required
for most DPI devices [22]. It will therefore be appreci-
ated that each DPI device is unique and each requires
its own ‘bespoke’ inhalation manoeuvre that should be
correctly understood by both the patient and the
healthcare professional. In contrast, all pMDIs only
require the same ‘generic’ inhalation manoeuvre from
each device. The concerning scenario for the patient is
when they are given a pMDI as a reliever medication,
a DPI to deliver their maintenance treatment, and a
nebuliser to give them added bronchodilation; that is, a
prescription of three different devices each requiring
different inhalation manoeuvres – no wonder patients
don’t know how to use devices effectively and are con-
fused! In clinical practice we should try to stratify de-
vices so that the reliever treatment and maintenance
therapy are given by the same type of device in order to
allow the same inhalation manoeuvre for both; that is,
either two similar device types (both pMDIs or both
DPIs) or, in the case of patients with asthma, the option
of the use of two drugs delivered from one device using
the maintenance and reliever therapy approach [23].
Certainly in asthma, it has been shown that patients
prescribed the same type of device are more likely to
achieve better disease control than those prescribed
mixed inhalation device types [24]. The use of devices to
assess the patient’s inhalation technique (AIM, In-Check
dial, 2-Tone trainer), with some mimicking the internal re-
sistance of various inhalers, may also provide significant
advantages. These can be used to confirm adequacy of
peak inspiratory flow (PIF) either when first prescribing a
new device in a patient, or in their regular training and
monitoring of inhaler use [25, 26].
Particle size and fine particle fraction
The characteristics of the aerosol particle size distribution
emitted from inhalation devices are important in directing
the inhaled drug to the target site of action in the lungs.
With this regards, the small airways have been extensively
reported to be significantly involved in the onset and pro-
gression of COPD and a target site of action for inhaled
therapy. However, due to their localization deep in the
lungs and their anatomical structure, they may not be eas-
ily reached by all drug/device products [27, 28],
Drug deposition in the bronchial tree is achieved
through different modalities [29]. Turbulence and iner-
tial impaction occur when larger particles deposit in
proximal airways, where the velocity of airflow is
maximal. Sedimentation allows suspended particles to
deposit through the force of gravity, rather than being
exhaled. Diffusion through Brownian motion is respon-
sible for the deposition of the submicron particles within
the airways. A drug particle size of between 2 to 5 mi-
crons has been shown to have the greatest potential to
be deposited throughout the bronchial tree [30]. In fact,
particles <2 micron deposit in the central airways but also
deeper into the acinar compartment, while particles >5
micron tend to deposit proximally in the central airways
or the oropharynx, where they produce no clinical effect
and give rise to the potential for the drug to be swallowed
and contribute to oral bioavailability and adverse side-
effects through gastrointestinal absorption. Two indices
commonly used to characterise the particle size distribu-
tion emitted from aerosols are: the mass median aero-
dynamic diameter (MMAD), which is the droplet size at
which half of the mass of the aerosol is contained in
smaller droplets and half in larger droplets [31], and the
fine particle fraction (FPF), meaning the proportion of
particles <5 microns in diameter [32]. Both these indices
can affect not only the total amount of drug reaching the
lungs (total lung deposition), but also the amount of drug
that is distributed between the central and distal lung
regions.
In a scientific study in patients with asthma involving in-
haled salbutamol aerosol particles of 1.5-, 3.0- and 6.0-
MMAD, it was observed that the smaller 1.5 micron parti-
cles achieved better total lung deposition and better distal
airways penetration compared to the larger particles [33, 34].
In clinical practice, commercial drug delivery devices with
smaller MMADs have now been developed that have been
shown to achieve greater levels of total lung deposition
(>40 %) compared to conventional larger drug particle de-
vices (<20 %) [35–38]. Specifically in patients with COPD,
small particle (~1.5 microns) drug formulations have been
shown to achieve as good levels of total lung deposition
(~33 %) in severely diseased patients (FEV1 43.6 ± 7.2 %of
predicted) compared to healthy subjects with normal levels
of lung function [39]. Inhalation devices have also been de-
signed to have an emitted aerosol with a higher FPF [40],
which have also been shown to achieve more distal airways
deposition [41, 42].
The velocity at which an aerosol exits the device is
also an important determinant of the regional distribu-
tion of drug reaching the lungs. It has been show that a
slow-moving velocity aerosol, coupled with a smaller
drug particle size, achieves effective (>50 %) total depos-
ition in the lungs and also penetration into the distal air-
way tree [38, 43].
Inhaler training and education
Patient training and education in inhaler use and inhal-
ation therapy is often overlooked in busy clinics, yet
Bonini and Usmani COPD Research and Practice  (2015) 1:9 Page 3 of 9
critically the correct use of an inhaler by a patient is
directly related to the efficacy of therapy. In other
words, misuse of inhalers is directly linked to poor dis-
ease control [7–9]. Healthcare providers should not as-
sume that the correct use of a device is intuitive or
obvious from the accompanying drug patient informa-
tion leaflet and instructions. Indeed, professionals
should also not rely on only verbal communication ei-
ther, but rather provide a comprehensive approach with
a “step by step” practical hands-on demonstration on
the use of the inhalation devices [44]. And this is, in it-
self, not enough since a retrospective study showed that
almost 54 % of patients stopped their medications peri-
odically over a period of 3 months [45]. International
strategy documents [3] therefore recommend that in-
haler re-education and re-training should be repeated
at each visit with a healthcare professional, and that pa-
tients should be encouraged to bring their inhalers to
demonstrate their inhalation technique. Education
should also focus on the rationale why the patient
needs the inhaler and on the importance of its regular
and pertinent use [46].
Incorrect inhaler technique is a critical factor prevent-
ing patients with COPD from receiving the optimal ben-
efits of their prescribed medications (up to 90 % of
patients in clinical studies) [47], and particularly in the
elderly population and in the late stages of the disease. It
has in fact been shown that error rates related to device
handling increase with age and with the degree of air-
flow obstruction [48–50]. COPD itself is a disease of
ageing and elderly patients may suffer from cognitive
impairments, hearing and visual problems, or other
physical disabilities that potentially all contribute to
affect their ability to understand and follow treatment
regimens [51]. In addition, aged and severely ill patients
are often affected by multiple chronic comorbidities re-
quiring multiple medications through different routes of
administration, and treatment complexity is a well-rec-
ognized risk factor for poor adherence [52]. A poor device
technique is also potentially responsible for relevant eco-
nomic consequences, considering that of an estimated $25
billion spent for inhalers annually, $5–7 billion is wasted
because of inhaler misuse [53].
Most importantly, education needs to be directed at
healthcare professionals; if they do not know how to use
inhaler devices properly, how are they going to teach
their patients? In a study by Hanania and colleagues,
performed over 20 years ago, respiratory physicians were
the most uncertain in the correct use of a range of inhal-
ation devices (pMDIs, DPIs and spacers) in contrast to
respiratory nurses or physiotherapists [54]. The authors
concluded that medical doctors in particular need add-
itional instruction in inhaler usage during their training.
However, the passage of time has not improved matters.
In a recent study, only 14 % of over 1500 physicians sur-
veyed had adequate knowledge of inhaled therapy and of
these, less than 50 % knew the correct inhalation
manoeuvre required from a DPI device and only ~25 %
checked the inhalation technique of the patient before
prescribing a new device/drug combination [55].
Once treatment is initiated, adherence to the recom-
mended therapeutic regimen is critical for achieving
clinical benefits, particularly for long-term use therapies,
and must be distinguished from compliance: the differ-
ence being in the patient’s willingness to accept therapy.
The non-compliant patient merely ignores prescriptions,
while the non-adherent one fails to properly follow them
despite the willingness to assume therapies [56]. Import-
antly, patients should be engaged in the decision of in-
haler device prescription and the patient’s preference
should not be ignored [57], as it may significantly affect
the effectiveness of inhalation therapy. An inhaler device
should not be changed without consulting the patient
and in the study by Doyle and colleagues, they showed
that switching a patient’s inhaler without their consent
could diminish the self-control associated with good
asthma management, leave the doctor-patient relation-
ship damaged, and increase resource utilisation and
waste medication [58]. Healthcare providers should
therefore very carefully evaluate which device is appro-
priate to the clinical needs and wishes of the patient
[57]. Taken together, the above observations emphasize
the central role played by devices in clinical practice and
support the importance of an adequate inhaler choice
for optimal control of the disease.
Inhaler devices for treating COPD patients
Aerosols are either solutions containing the medication or,
solid drug particles suspended in a gas or in a dry powder.
Aerosols can be delivered from different pMDIs, DPIs and
nebulisers. In recent years, several technological innova-
tions in device engineering and formulation science have
significantly improved the performance of all existing cat-
egories of inhalation devices, and some highly effective de-
livery systems have been developed (Table 1). The new
‘generation’ of inhalers have pulmonary deposition frac-
tions of 40–50 % of the nominal dose, which are consider-
ably higher compared with the 10–15 % that inhalers
currently used in clinical practice achieve [59].
From the 19th century until the 1950’s, compressed-
air nebulizers were the main device in clinical use for
the administration of inhaled aerosolised drugs to re-
spiratory patients. The first commercial pMDI was de-
veloped by Riker Laboratories in 1956 as a portable,
multi-dose delivery system for bronchodilator drugs.
Since then, the pMDI has become the most commonly
prescribed inhaler device for drug delivery to the bron-
chial tree [60]. The relatively low cost and the wide
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variety of medications available in the pMDI device have
contributed to the popularity of this delivery system.
However, the correct use of pMDIs requires a slow and
deep inhalation and a certain degree of coordination be-
tween inhalation and device actuation. Too fast inhal-
ation through a pMDI device and lack of coordination
can both contribute to ineffective drug delivery to the
lungs with excess deposition in the oropharynx [7]. To
circumvent these issues, the combined use of a pMDI
plus spacer is often recommended, especially for elderly
patients who may have problems with dexterity and co-
ordination. However, spacers were developed primarily
to be used with the old chlorofluorocarbon (CFC) pro-
pellant pMDIs (which are now obsolete) mainly to
achieve three key outcomes; (i) to create a ‘space’ for the
fast aerosol plume to slow down and achieve a slow vel-
ocity prior to inhalation at the mouth, in order to de-
crease oropharyngeal deposition, (ii) to provide a
distance in order for the CFC-propellant to evaporate
and produce smaller drug particles prior to inhalation
and thereby achieve more effective lung deposition and,
(iii) to allow patients to comfortably inhale the drug
from a ‘holding chamber’, thereby decreasing the need
for coordination on actuation. However, the need for
spacers with the newer generation of hydrofluoroalkane
(HFA) pMDIs, and particularly HFA-solution pMDIs,
may be far less, as these devices have slower velocity
aerosols with a smaller drug particle size or fine particle
fraction. In addition, some of the newer pMDIs are less
flow dependent; that is, there is consistency of dose de-
livery to the lungs irrespective of the inhalation flow of
the patient [40].
The first generation of pMDIs consisted of aluminium
canisters, containing a pressurised suspension of mi-
cronized drug particles dispersed in chlorofluorocarbon
(CFC) propellants. In suspension formulations, the ac-
tive drug is not soluble in the propellant and remains
as a solid powder within the container. Consequently,
the inhaler must be shaken prior use to ensure uni-
form distribution of the particles and a constant emitted
dose at each use. Failure to shake the device has been
shown to reduce the delivery of both beta-2 agonists
and corticosteroids by up to 50 % [61]. Furthermore,
studies report that not shaking the device between suc-
cessive dosages can also reduce drug delivery [62].
Much of the innovation in pMDI development arose
from the Montreal Protocol declaration banning the
use of CFCs, and the pharmaceutical industries
Table 1 Principal features of available inhalers
Device Type Advantages Disadvantages
Pressurisedmetered-dose inhalers
(pMDI’s)
• CFC driven (obsolete) Portable and compact Ozone-depleting properties (CFC driven)
• HFA driven Independent of inspiratory
flow
Better perform with spacers (CFC driven)
• Breath-actuated Reproducible dosing Need to be shaken prior use (CFC driven)
No contamination risk Require coordination between actuation and inspiration
(CFC and HFA driven)
Quick and easy to use High oropharyngeal deposition




Dry powderinhalers (DPI’s) • Single-dose Portable and compact Inspiratory flow dependent
• Multi-dose Do not require coordination Poor dose reproducibility
• Power-assisted Quick and easy to use Affected by environmental factors (i.e. humidity)
No spacer required
Soft-mist inhaler Portable Dose loading into device
Slow velocity aerosol
Long plume duration
Does not require coordination
No propellant
No spacer required
Nebulisers • Jet Propellant free Bulky equipment
• Vibrating mesh High patient’s adherence More complex use
• Ultrasonic Slow velocity aerosol Power source
Requires frequent cleaning
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developed HFA propellants for the new pMDIs that did
not have ozone-depleting properties [63]. The transi-
tion from CFC to HFA propellants has allowed the op-
portunity for formulation scientists to develop pMDI
solution formulations, and particularly HFA- solution
pMDI aerosols in which the drug is uniformly distrib-
uted in the canister, which therefore doesn’t need to be
shaken prior to use [63].
Breath-activated pMDI (BA-pMDI) devices have been
available for a good few years, and have been shown to
be helpful in patients with poor coordination issues as-
sociated with conventional pMDIs [64]. BA-pMDI’s con-
tain a conventional pressurised canister, with a flow-
triggered system driven by a spring, which releases the
drug dose during inhalation, so that firing and inhaling
are automatically coordinated. BA-pMDIs can be actu-
ated at a low patient inhalation flow which is readily
achievable by most patients. However, data report drug
deposition in the lungs of patients using BA-pMDI’s is
not that different to patients with good coordination
using a press-and-breathe pMDI of the same formula-
tion, but only significantly higher compared to those
patients with a poor coordination [64, 65]. More re-
cent studies have shown improved drug deposition
and increased patient confidence related to successful
dosing with the use of BA-pMDI’s [66, 67]. Prescribing
BA-pMDI’s to COPD patients may therefore improve dis-
ease control reducing health care costs, in spite of the in-
creased device costs, but the greatest limiting factor is the
availability of a variety of drug molecules in this particular
device. Further advances continue in pMDI technology,
and are represented by innovative devices which in-
corporate small microprocessors. These ‘intelligent’ in-
halers allow the patient’s inhalation to be controlled and
their adherence to be monitored [64]. These develop-
ments may offer significant improvements to conventional
pMDI’s, but still require careful analyses to estimate
patients’ clinical benefits and justification for additional
expenses.
In 1971, Bell and colleagues introduced the first DPI
to deliver therapy to patients with COPD [68]. Since
then, a diverse number of DPI devices are currently
available to treat patients with COPD, each with its
own different handling instructions and each with its
own ‘bespoke’ inhalation manoeuvre. Based on their de-
sign, DPIs can be classified into three different categor-
ies: the first generation, single-dose DPIs; the second
generation, multiple-dose DPIs, and the third gener-
ation DPIs, ‘active’ or power-assisted DPIs. The major
advantage of DPIs is that they do not require coordi-
nated activation. However, in a similar manner to
pMDIs, there are marked differences between the lung
deposition from different DPI devices. DPI devices can
be flow-dependent leading to variability in drug delivery
to the lungs based on the inhalation flow of the patient
through the device [62, 69]. In addition, most conven-
tional DPIs are inherently dependently on the energy in
the patient’s breath during inhalation to de-aggregate
and disperse the dry powder contained within the de-
vice, and these factors may lead to low levels of drug
deposition (~20 %) to the lungs at low patient inhal-
ation flows [70, 71]. However, recent innovations in
DPI engineering and chemistry have advanced this de-
vice category with a newer generation of inhalers that
are activated at low (and not high) patient inhalation
flows (~30 l/min or less) and achieve far better levels of
lung deposition (>40 %) [72]. DPIs have been also de-
veloped with small particle dry-powder formulations in-
haled at low inhalation flows achieving high (>40 %)
levels of lung deposition [42].
There are a variety of nebulisers - such as jet, vi-
brating mesh and ultrasonic - available on the market
that are used mainly with bronchodilator agents in
patients with COPD, and each has a variable perform-
ance based on the specific model [73, 74], A newer
generation of nebulisers have been developed that
aim to decrease the inefficiency, waste, and variability
of nebulized drug delivery. Some vibrating mesh disk
nebulisers, powered by a compressor and containing a
microchip, control drug delivery to the patient and
have an adaptive aerosol system that is able to pulse
the inhaled drug during the inhalation phase therefore
leading to less dose wastage, as well as to provide de-
tailed feedback on each treatment, and have been
shown to improve the patient’s adherence [75]. A
smart nebuliser system has been developed that con-
tains an electronic smart-card unit with an air com-
pressor, which is coupled to either jet or vibrating
mesh nebulisers and operates to accurately dose and
target aerosol delivery, and studies have shown better
efficacy compared to standard nebulisers and are an
excellent driver for patients’ adherence [76, 77]. New
hand-held multi-dose nebuliser devices have also been de-
veloped that have the potential to compete with both
pMDIs and DPIs on the portable inhaler market [75].
A unique device that has the attributes of a nebu-
liser (being propellant free), but also that of a pMDI
(hand-held and portable), and that of a spacer (allow-
ing a slow exit velocity aerosol) was developed over a
decade ago and has been categorised as a ‘soft-mist’
inhaler [78]. This device atomises the drug solution
using mechanical energy imparted by a spring, produ-
cing a fine, slow-moving mist, where aerosol spray
duration is considerably longer (approximately 1.2 s)
compared to that for pMDI’s (0.15-0.35 s) and these
features lead to low levels of drug deposition in the
oropharynx and effectively high total lung deposition
(>50 %) [79]. Indeed this device has additional
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technological advances with a small drug particle size
(an average MMAD of 2 microns), together with a
high FPF (~75 %) which both contribute to effective
distal airway lung deposition to target the site of dis-
ease in patients with COPD [38].
Conclusions
Inhalation therapy is the mainstay of treatment in pa-
tients with COPD. Collected data show that in the last
years, several innovative and significant developments
have been achieved in the field of device engineering
and formulations. Physicians can count on a broad var-
iety of device categories with features all providing ef-
fective aerosol delivery for COPD treatment. Indeed, it
seems a perfect inhaler does not exist and each has its
advantages and limitations. In fact, ensuring effective in-
halation and drug delivery to the target site depends on
many factors, which ultimately impact on patients’ re-
sponse to treatment. In daily practice, an appropriate in-
haler choice should therefore carefully take into
consideration not only device related aspects such as
aerosol velocity and drug particle size, but also patients’
pulmonary function (inhalation flow), skills (dexterity,
cognition) and preferences. Unfortunately, however little
has been done to sensitize the healthcare provider com-
munity to the relevance of these aspects. Furthermore,
despite a good amount of reliable evidence in literature,
few and vague recommendations are provided by inter-
national strategy documents and respiratory scientific
societies. This situation results in a reduced efficacy of
inhalation therapy and in a waste of financial resources.
Efforts are therefore critically needed to improve health-
care provider knowledge and education of inhalation de-
vices in order to optimise clinical benefits for their
patients and positively influence both doctor-patient sat-
isfaction with aerosol therapy.
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